[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Big Pharma Split Corp (PRM.TO)

Big Pharma Split Corp (PRM.TO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Balance Sheet for [[ item.sessionDateDisplayLong ]]

Fiscal Year End Date: 12/31

(Values in thousands)
  12-2020 12-2019 12-2018 12-2017
Assets
Cash & Cash Equivalents 231 536 417 1,846
Receivables 104 73 70 16
Other assets 22,597 26,567 33,144 30,626
Total Assets $22,933 $27,177 $33,631 $32,487
Liabilities
Accounts payable and accrued liabilities 213 N/A 306 210
Other liabilities 9,534 10,867 14,482 13,600
Total Liabilities $9,747 $10,867 $14,788 $13,811
Shareholders' Equity
Other shareholders' equity 13,185 16,309 18,843 18,677
TOTAL $13,185 $16,309 $18,843 $18,677
Total Liabilities And Equity $22,933 $27,177 $33,631 $32,487
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.